J&J may acquire Intra-Cellular Therapies to expand neuroscience portfolio, addressing revenue challenges

From Investing.com: 2025-01-12 19:32:35

Johnson & Johnson is reportedly considering acquiring Intra-Cellular Therapies, a biopharmaceutical company, in a deal that could be finalized as early as this week. Intra-Cellular has a market value of around $10 billion and is known for its FDA-approved treatment for schizophrenia and bipolar disorders, Caplyta.

The potential acquisition could help J&J expand its neuroscience portfolio and address revenue challenges from patent expirations on its blockbuster drugs. Discussions are in early stages, with no final decision made yet. Intra-Cellular shares surged nearly 15% on Friday in anticipation of a deal.

J&J is actively pursuing growth in high-growth therapeutic areas to strengthen its pharmaceutical division amidst increasing competition. No formal deal is guaranteed as negotiations continue with Intra-Cellular.



Read more at Investing.com: J&J explores takeover bid for Intra-Cellular Therapies, Bloomberg reports By Investing.com